NOVEN PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 610
- Market Cap
- -
- Website
- http://www.noven.com
Irritation and Sensitization Study of HP-5000 Topical System
Phase 1
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: HP-5000 Topical PatchDrug: HP-5000 Placebo PatchDrug: Saline Patch
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT04882319
- Locations
- 🇺🇸
TKL Research, Fair Lawn, New Jersey, United States
A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee
Phase 3
Completed
- Conditions
- Osteoarthritis Pain of the Knee
- Interventions
- Drug: Placebo patch
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 370
- Registration Number
- NCT04683627
- Locations
- 🇺🇸
Noven Pharmaceuticals, Inc., Jersey City, New Jersey, United States
🇺🇸Partners in Clinical Research, Cumberland, Rhode Island, United States
🇺🇸Palmetto Clinical Research, Summerville, South Carolina, United States
Study Will Assess Skin Irritation and Sensitization for HP-1050 Patch
Phase 1
- Conditions
- Cumulative Irritation and Sensitization
- Interventions
- Drug: HP-1050 Patch
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04624867
- Locations
- 🇺🇸
QPS Missouri, Springfield, Missouri, United States
A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis
Phase 2
Completed
- Conditions
- Osteoarthritis of the Knee
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2021-12-23
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 289
- Registration Number
- NCT03277066
- Locations
- 🇺🇸
Noven Pharmaceuticals, Inc., Jersey City, New Jersey, United States
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: Low Dose Asenapine maleate transdermal patchDrug: High Dose Asenapine maleate transdermal patchDrug: Placebo
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 617
- Registration Number
- NCT02876900
- Locations
- 🇺🇸
Noven Pharmaceuticals, Inc., Jersey City, New Jersey, United States
Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD
Phase 2
Completed
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo patch
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Noven Pharmaceuticals, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT01711021
- Locations
- 🇺🇸
University of California - Irvine, Irvine, California, United States
🇺🇸Center for Psychiatry and Behavioral Medicine Inc., Las Vegas, Nevada, United States
🇺🇸Florida International University Center for Children and Families, Miami, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath